The termination does not impact Medtronic’s fiscal year 2024 adjusted earnings per share guidance range that the company provided on November 21, 2023. Medtronic continues to advance its automated insulin dosing product pipeline, including a differentiated patch pump.
Related Posts
US Stock Futures Waver After 7-Week Winning Streak: Analyst Sees More Gains Piling Up On Dow’s Record Highs
U.S. stock futures indicate a cautious opening on Monday after the market’s seven consecutive weekly winning streak. As the time…
C3.ai Q2 Earnings Highlights: Revenue Miss, EPS Beat, ‘Unprecedented Interest And Traction’ In Generative AI Offerings
C3.Ai Inc (NYSE:AI) reported fiscal second-quarter financial results Wednesday after the bell. Here’s a look at the key metrics from the…
Chevron Reveals $16B Of 2024 Capex Budget
Upstream spending in 2024 is expected to be about $14 billion. Downstream capex is expected to be roughly $1.5 billion, with 80 percent allocated to…